Neoadjuvant PD-1 Blockade Enables Patients with Mismatch Repair Deficient Colorectal Cancers to Avoid Surgery

An interview with: Andrea Cercek MD, Gastrointestinal Cancer Medical Oncologist, Memorial Sloan Kettering Cancer Center, New York And: Ryan B Corcoran MD PhD, Director of the GI Cancer Program, Massachusetts General Hospital Cancer Center, Boston MA CHICAGO—The Audio Journal of Oncology reports on the neoadjuvant use of programmed cell-death protein 1 (PD-1) immune checkpoint inhibition to give patients whose resectable colorectal cancers express mismatch repair deficiency the option of avoiding surgery. Early results from a phase two trial with the PD-1 blocker dostarlimab were reported at the 2025 Annual Meeting of the American Association for Cancer Research held in Chicago. At the meeting the Audio Journal’s correspondent Peter Goodwin met up with the study first author, Andrea Cercek MD, a gastrointestinal cancer medical oncologist from Memorial Sloan Kettering Cancer Center in New York. AACR Abstract title: “Non operative management of mismatch repair deficient tumors”

There are no comments yet.

Please log in to write the first comment.